InstrumentpanelPortföljerBevakningslistaGemenskapUpptäckSkärm
NOT FOR DISTRIBUTION

Stratec SE

XTRA:SBS Aktierapport

Börsvärde: €302.7m

  • Översikt över företaget
    • Värdering
    • Framtida tillväxt
    • Tidigare resultat
    • Finansiell hälsa
    • Utdelning
  • Förvaltning
  • Ägarskap
  • Övrig information
  • Aktiegemenskap

Stratec Framtida tillväxt

Future kriterier kontrolleras 4/6

Stratec förväntas öka intäkter och intäkter med 37.2% respektive 7.5% per år. EPS förväntas tillväxt med 37.7% per år. Avkastningen på eget kapital förväntas bli 9% om 3 år.

Viktig information

37.2%

Tillväxttakt i vinsten

37.66%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt11.9%
Intäkternas tillväxttakt7.5%
Framtida avkastning på eget kapital8.96%
Bevakning av analytiker

Good

Senast uppdaterad17 Sep 2026

Senaste uppdateringarna om framtida tillväxt

Analysartikel • Nov 11

Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Stratec SE ( ETR:SBS ) shareholders are probably feeling a little disappointed, since its shares fell 5.2% to €21.75 in...

Recent updates

User avatar
Uppdatering av berättelse • Jun 17

SBS: Future Upside Will Rely On Reset Margins And Lower P/E

Analysts have trimmed their price target on Stratec stock by €2 to reflect updated assumptions on fair value, discount rate, growth and profitability. This has resulted in a lower overall valuation framework for the company.
User avatar
Uppdatering av berättelse • Jun 02

SBS: Lowered Multiples And Stable Margins Will Support Future Upside Potential

Analysts have trimmed their price targets for Stratec, with recent cuts of €2 at Deutsche Bank and to €34 from €46 at Berenberg. These changes reflect updated views on revenue growth, profit margins and future P/E assumptions.
User avatar
Uppdatering av berättelse • May 08

SBS: Lower Growth Assumptions Will Still Allow Future Upside Potential

The analyst fair value estimate for Stratec has been revised from about €26.00 to about €20.00, as analysts trim price targets and factor in lower revenue growth assumptions, softer profit margin expectations, and a higher implied future P/E, in line with recent target cuts from major banks. Analyst Commentary Recent Street research reflects a more cautious stance on Stratec, with price targets revised lower and expectations reset around revenue growth and profitability.
User avatar
Uppdatering av berättelse • Apr 21

SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential

The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
User avatar
Uppdatering av berättelse • Apr 06

SBS: Future Upside Will Rely On Reset Margins And Higher P/E

Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.
User avatar
Uppdatering av berättelse • Mar 23

SBS: Future Upside Will Depend On Repriced Earnings Power And Margins

Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.
User avatar
Uppdatering av berättelse • Mar 09

SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside

Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.
User avatar
Uppdatering av berättelse • Feb 22

SBS: Higher Discount Rate Will Still Allow Future Upside Potential

Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.
User avatar
Uppdatering av berättelse • Feb 08

SBS: Future Upside Will Rely On Earnings Power And Cost Controls

Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.
User avatar
Uppdatering av berättelse • Jan 23

SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls

Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.
Analysartikel • Jan 10

Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
User avatar
Uppdatering av berättelse • Jan 08

SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential

Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.
User avatar
Uppdatering av berättelse • Dec 18

SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective

Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.
User avatar
Uppdatering av berättelse • Dec 04

SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold

Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.
Analysartikel • Nov 29

Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
User avatar
Uppdatering av berättelse • Nov 20

SBS: Margins Will Improve With Cost Management And Leadership Changes

The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.
Analysartikel • Nov 11

Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Stratec SE ( ETR:SBS ) shareholders are probably feeling a little disappointed, since its shares fell 5.2% to €21.75 in...
Analysartikel • Nov 07

Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding

Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop...
User avatar
Uppdatering av berättelse • Nov 03

SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures

Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.
Analysartikel • Sep 23

Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult

Stratec SE's ( ETR:SBS ) price-to-earnings (or "P/E") ratio of 25.3x might make it look like a sell right now compared...
User avatar
Uppdatering av berättelse • Aug 23

Automation And Digitalization Will Transform Healthcare Diagnostics

Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.
Analysartikel • Jun 17

An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued

Key Insights Stratec's estimated fair value is €36.05 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...
Analysartikel • Apr 25

Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price

With a price-to-earnings (or "P/E") ratio of 30.8x Stratec SE ( ETR:SBS ) may be sending very bearish signals at the...
User avatar
Ny berättelse • Feb 09

Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence

Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.
Analysartikel • Jan 18

An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Stratec fair value estimate is €55.10 Stratec's €32.10 share...
Analysartikel • Nov 09

With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For

Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 25% after a relatively good period beforehand. The drop...
Analysartikel • Oct 26

Returns At Stratec (ETR:SBS) Appear To Be Weighed Down

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
Analysartikel • May 11

Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year

Key Insights Stratec to hold its Annual General Meeting on 17th of May Total pay for CEO Marcus Wolfinger includes...
Analysartikel • Apr 11

Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55

Stratec SE's ( ETR:SBS ) dividend is being reduced from last year's payment covering the same period to €0.55 on the...
Analysartikel • Apr 01

Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next

Shareholders might have noticed that Stratec SE ( ETR:SBS ) filed its yearly result this time last week. The early...
Analysartikel • Mar 28

Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55

The board of Stratec SE ( ETR:SBS ) has announced it will be reducing its dividend by 43% from last year's payment of...
Analysartikel • Dec 21

Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?

Key Insights Stratec's estimated fair value is €67.40 based on 2 Stage Free Cash Flow to Equity Stratec's €43.00 share...
Analysartikel • Nov 03

Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysartikel • Oct 19

We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Prognoser för vinst- och omsättningstillväxt

XTRA:SBS - Analytikernas framtida uppskattningar och tidigare finansiella data (EUR Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20282972016315
12/31/20272831815316
12/31/20262621334535
6/30/202624502235N/A
3/31/2026244-31024N/A
12/31/20252510-170N/A
9/30/202526015322N/A
6/30/202526415726N/A
3/31/2025267172443N/A
12/31/2024258163149N/A
9/30/2024256131834N/A
6/30/2024258171633N/A
3/31/202425212-116N/A
12/31/202327015219N/A
9/30/202325512-22-1N/A
6/30/202326219-31-11N/A
3/31/202326019-515N/A
12/31/202227529-910N/A
9/30/2022270281835N/A
6/30/2022269273755N/A
3/31/2022291403050N/A
12/31/2021287404363N/A
9/30/2021296464063N/A
6/30/2021286412953N/A
3/31/2021266352043N/A
12/31/202025028632N/A
9/30/202023524529N/A
6/30/202022521-420N/A
3/31/202022417N/A15N/A
12/31/201921414N/A21N/A
9/30/201921214N/A8N/A
6/30/201920714N/A13N/A
3/31/201919511N/A9N/A
12/31/201818811N/A12N/A
9/30/201819316N/A20N/A
6/30/201819723N/A28N/A
3/31/201819824N/A28N/A
12/31/201720727N/A30N/A
9/30/201720828N/A30N/A
6/30/201720620N/A21N/A
3/31/201720319N/AN/AN/A
12/31/201618519N/A16N/A
9/30/201616614N/A17N/A
6/30/201615519N/A23N/A
3/31/201614421N/AN/AN/A
12/31/201514722N/A26N/A
9/30/201514722N/A35N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: SBS förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 2.1% ).

Resultat vs marknad: SBS förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: SBS förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: SBS s intäkter ( 7.5% per år) förväntas växa snabbare än German marknaden ( 6.6% per år).

Hög tillväxtintäkter: SBS s intäkter ( 7.5% per år) förväntas växa långsammare än 20% per år.


Tillväxtprognoser för vinst per aktie


Framtida avkastning på eget kapital

Framtida ROE: SBS s avkastning på eget kapital förväntas bli låg om 3 år ( 9 %).


Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/09/17 18:45
Aktiekurs vid dagens slut2026/09/17 00:00
Intäkter2026/06/30
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
  • SEC Form 10-K
  • SEC Form 10-Q
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
  • Rapporter från analytiker
  • Blue Matrix
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
  • ICE Marknadsdata
  • SEC Form S-1
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
  • SEC Formulär 4
  • SEC Formulär 13D
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
  • SEC Form 10-K
  • SEC Form DEF 14A
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden
  • SEC Formulär 8-K

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Stratec SE bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Michael HeiderBerenberg
Yi-Dan WangDeutsche Bank
Jan KochDeutsche Bank

Ta bättre investeringsbeslut var som helst

Skanna för att ladda ner
Öppna App StoreÖppna Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
Visa datakällor
Marknader
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investeringsidéer
  • Undervärderade bolag
  • Starka utdelningar
  • Insiderköp
  • Kärnenergi
  • Autonoma fordon
  • Artificiell intelligens
  • Krypto och blockkedja
  • Cybersäkerhet
  • Fler idéer
Lager Gemenskaperna
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Funktioner och verktyg
  • Portföljspårning
  • Aktieskärm och varningar
  • Berättelser & rättvisa värden
  • Kalkylator för utdelning
Nyheter & Upptäckter
  • Senaste lagernyheter
  • Global Market Insights
  • Foxhole-forumet
  • Investeringsidéer
  • Gemenskapens berättelser
  • Vad är nytt
Simply Wall St
  • Planer och priser
  • Annonsering
  • Om oss
  • Kontakta oss
  • Karriär
  • Hjälpcenter
  • Lär dig investera i aktier
  • Affiliate-program
  • Affärer & företag
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Villkor och anvisningar
  • Integritetspolicy
  • AI-villkor
  • Guide för finansiella tjänster